No Data
No Data
The market is weak, making it easier to sell on the rebound, but there is strong support at the lower level.
[Emerging Markets Individual Stock Strategy] Today, a weaker trend is expected in emerging markets. In the US stock market on the 27th yesterday, the Dow Jones average rose by $9.98 (+0.02%) to $41,250.50, slightly extending for the third consecutive day. The rise in long-term interest rates weighed on stock prices, while the unexpected improvement in the August consumer confidence index supported stock prices. In addition, with Nvidia's (NVDA) earnings report scheduled for the 28th, the high tech sector turned higher on expectations, supporting the market. The Dow reached an all-time high for consecutive days.
FRONTEO, Oncolis Biopharma, etc.
<2158> FRONTEO Corporation Capsule Medical Corporation shareholding ratio -% → 6.99%, obligation to report on August 14, 2024; <2158> FRONTEO Corporation Masahiro Morimoto shareholding ratio 18.16% → 10.25%, obligation to report on August 14, 2024; <3541> National Agriculture and Food Research Organization Hironori Horiuchi shareholding ratio 9.77% → 9.92%, obligation to report on the reporting date.
Inforich: (Correction) Correction of some information in the second quarter financial results explanatory materials for the December 2024 period.
Inforich to Establish UK Subsidiary for European Expansion
Supported by a firm US stock market, but there may be a heavy resistance to price increases.
[Emerging markets individual stock strategy] A strong development is expected in today's emerging markets. In the U.S. stock market on the 13th, the Dow Jones Industrial Average rebounded significantly by 408.63 points (+1.04%) to 39,765.64, due to a strong buying momentum that emerged following lower-than-expected July Producer Price Index (PPI) and expectations of a rate cut within this year. With growing confidence of interest rate cuts, investors heavily traded in high-tech stocks, and the market gains widened towards the end of the day. Today's emerging markets are expected to see a dominant trend of buying following yesterday's strong returns in major U.S. stock markets.
OncoLis Bio, Modaris, and others.
<4588> OncoReBio's 20th subscription rights (with exercise price adjustment clause and exercise suspension clause) issued 0.46 million shares of exercised stocks since the beginning of the month. <4883> Modaris' 12th subscription rights (with exercise price adjustment clause) completed the exercise and issued 2.227 million shares of exercised stocks since the beginning of the month. <9338> INFORIZCH established overseas subsidiaries in the United Kingdom. <9553> MicroAd transferred stocks with changes to its consolidated subsidiary (MADS). <4424> Amaizia with My Medical
No Data